North America Veterinary Oncology Market Report: Market Size & Forecast 2026

The North America veterinary oncology market covers companion-animal cancer care, including chemotherapy, immunotherapy, radiation therapy, surgical oncology, and diagnostic imaging services. With a 2026 valuation near $2.24 billion and a 12.0% annual growth trajectory, the segment is outpacing the wider North American veterinary medicine market, which was valued at roughly $19.2 billion in 2024 and is on track to surpass $31 billion by 2032. The United States and Canada together form the largest sub-regional market in the world for veterinary oncology, supported by an established network of specialty and referral hospitals.

• •2026 estimated market size of approximately $2.24 billion, representing a meaningful portion of the broader North American veterinary medicine sector
• •12.0% annual growth rate signals a rapidly expanding specialty segment within the overall veterinary services industry
• •Market is anchored by a well-developed companion-animal healthcare infrastructure across the U.S. and Canada

Elevated companion-animal cancer incidence, driven by longer pet lifespans and improved diagnostic screening, has significantly increased the pool of animals requiring oncology treatment. Advances in veterinary-specific chemotherapeutics, immunotherapies, and targeted therapies have expanded the clinical toolkit available to specialists. Broader adoption of pet insurance and wellness plans has reduced out-of-pocket barriers for owners, while growing consumer willingness to invest in premium animal healthcare continues to support demand.

• •Longer companion-animal lifespans and improved diagnostic capabilities have increased diagnosed cancer rates across dogs and cats
• •Expanding availability of veterinary insurance and pet wellness plans is reducing financial barriers to specialty oncology care
• •Ongoing development of new drug formulations and treatment modalities specific to veterinary applications is broadening addressable market scope

The market is predominantly segmented by animal type, with companion animals, particularly dogs and cats, accounting for the overwhelming majority of oncology spending. Treatment modality segmentation typically covers chemotherapy, immunotherapy, radiation therapy, and surgical options. Geographically within North America, the United States constitutes the largest share, reflecting higher veterinary specialty hospital density and greater owner spending power, while Canada represents a smaller but steadily growing secondary market.

• •Companion animals (dogs and cats) dominate the market, while equine and production-animal oncology remains a niche segment
• •The U.S. commands the largest share of North American veterinary oncology revenue due to higher concentrations of specialty referral centers and advanced diagnostic infrastructure
• •Canada contributes a growing, smaller share, with market expansion tied to rising specialty care awareness and cross-border referral networks

Who are the notable companies in the industry?

The competitive structure reflects a partially consolidated landscape with a tier of large, diversified animal health organizations alongside a broader field of mid-sized and smaller specialty oncology operators and independent referral hospitals. Integrated pharmaceutical and animal health producers supply a significant share of oncology drug portfolios, while independent specialty clinics and hospital groups dominate service delivery. Capacity is most heavily concentrated in major metropolitan corridors of the United States, with secondary hubs emerging in Canadian urban centers.

• •The industry sits between full consolidation and fragmentation: a core group of large diversified animal health companies coexists with numerous independent specialty oncology practices
• •Technology and treatment routes span conventional chemotherapy compounding, targeted small-molecule agents, immunotherapies (including cancer vaccines), and radiation platforms sourced from both general and specialty veterinary supply chains
• •Production and service capacity is heavily concentrated in high-density U.S. metropolitan areas, with secondary concentration along the U.S.-Canada border corridor

What are the recent trends and outlook?

Key trends shaping the sector include a clear shift toward precision oncology approaches, including targeted therapies and immunotherapies modeled on human oncology advances, and the growing integration of digital diagnostic tools such as AI-assisted imaging and tele-oncology consult platforms. Consolidation through mergers and acquisitions among specialty hospital operators is accelerating, while emerging treatment modalities and companion-animal clinical trial pipelines promise continued product pipeline expansion. The market is widely projected to sustain double-digit growth through the early 2030s, driven by the compounding effects of demographic, technological, and consumer-behavior shifts.

• •Precision oncology, including targeted therapies and immunotherapy, is increasingly mirroring human oncology innovation trends in veterinary applications
• •AI-powered diagnostic imaging and digital pathology tools are beginning to enter routine clinical workflows at leading specialty centers
• •Double-digit growth is expected to continue through at least 2030-2032, supported by expanding treatment options, growing pet insurance enrollment, and ongoing specialization of veterinary medical services